Hypoxia-induced retinal neovascularization in zebrafish embryos: A potential model of retinopathy of prematurity

PLoS ONE

Volumn 10, Issue 5, 2015, Pages

  Wu, Yu Ching ^a   Chang, Chao Yuan ^b   Kao, Alex ^a   Hsi, Brian ^a   Lee, Shwu Huey ^c   Chen, Yau Hung ^b   Wang, I Jong ^a  

^a NATIONAL TAIWAN UNIVERSITY HOSPITAL   (Taiwan)

^b TAMKANG UNIVERSITY   (Taiwan)

^c CATHAY GENERAL HOSPITAL   (Taiwan)

Author keywords

[No Author keywords available]

Indexed keywords

BEVACIZUMAB; COBALT CHLORIDE; MESSENGER RNA; RANIBIZUMAB; SEMAXANIB; VASCULOTROPIN A; VASCULOTROPIN RECEPTOR 2;

ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ARTICLE; BLOOD VESSEL WALL; CONTROLLED STUDY; DRUG EFFECT; EMBRYO; GENE EXPRESSION; HYPOXIA; IN VIVO STUDY; NONHUMAN; RETINA ANGIOGRAPHY; RETINA BLOOD VESSEL; RETINA NEOVASCULARIZATION; RETROLENTAL FIBROPLASIA; SIGNAL TRANSDUCTION; VEGFAA GENE; VEGFR2 GENE; ZEBRA FISH; ANIMAL; DISEASE MODEL; LARVA; METABOLISM; NEOVASCULARIZATION (PATHOLOGY); NEWBORN; PATHOLOGY; RETINA; VASCULAR ENDOTHELIUM;

DANIO RERIO;

ANIMALS; ANIMALS, NEWBORN; DISEASE MODELS, ANIMAL; ENDOTHELIUM, VASCULAR; HYPOXIA; LARVA; NEOVASCULARIZATION, PATHOLOGIC; RETINA; RETINAL NEOVASCULARIZATION; RETINAL VESSELS; RETINOPATHY OF PREMATURITY; RNA, MESSENGER; VASCULAR ENDOTHELIAL GROWTH FACTOR A; ZEBRAFISH;

EID: 84929300700     PISSN: None     EISSN: 19326203     Source Type: Journal    
DOI: 10.1371/journal.pone.0126750     Document Type: Article

References (59)

1. Sukbuntherng J, Cropp G, Hannah A, Wagner GS, Shawver LK, Antonian L. Pharmacokinetics and interspecies scaling of a novel VEGF receptor inhibitor, SU5416. The Journal of pharmacy and pharmacology. 2001;53(12):1629-36. doi: 10.1211/0022357011778232 PMID: 11804393
2. Foster A, Gilbert C. Epidemiology of childhood blindness. Eye (London, England). 1992;6(Pt 2)(2):173-6. doi: 10.1038/eye.1992.34
3. Chawla D, Agarwal R, Deorari A, Paul VK, Chandra P, Azad RV. Retinopathy of prematurity. The Indian Journal of Pediatrics. 2012;79(4):501-9.
4. Good WV, Hardy RJ, Dobson V, Palmer EA, Phelps DL, Quintos M, et al. The incidence and course of retinopathy of prematurity: findings from the early treatment for retinopathy of prematurity study. Pediatrics. 2005;116(1):15-23. doi: 10.1542/peds.2004-1413 PMID: 15995025
5. Flynn JT. The premature retina: a model for the in vivo study of molecular genetics? Eye (London, England). 1992;6(Pt 2)(2):161-5. doi: 10.1038/eye.1992.32
6. Gariano RF, Gardner TW. Retinal angiogenesis in development and disease. Nature (London). 2005;438(7070):960. PMID: 16355161
7. Chen J, Smith LE. Retinopathy of prematurity. Angiogenesis. 2007;10(2):133-40. PMID: 17332988
8. Smith LEH. Pathogenesis of retinopathy of prematurity. Acta Pædiatrica. 2002;91(Supplement 437):26-8. doi: 10.1111/j.1651-2227.2002.tb00157.x
9. The Committee for the Classification of Retinopathy of Prematurity. An International Classification of Retinopathy of Prematurity. Archives of Ophthalmology. 1984;102(8):1130-4. doi: 10.1001/archopht. 1984.01040030908011 PMID: 6547831
10. Adamis AP, Patel M, Altaweel M, Bressler NM, Cunningham JET, Davis MD, et al. Changes in Retinal Neovascularization after Pegaptanib (Macugen) Therapy in Diabetic Individuals. Ophthalmology. 2006;113(1):23-8. doi: 10.1016/j.ophtha.2005.10.012 PMID: 16343627
11. Ferrara N. The role of VEGF in the regulation of physiological and pathological angiogenesis. Basel: Birkhäuser Basel; 2005. p. 209-31.
12. Jorge R, Costa RA, Calucci D, Cintra LP, Scott IU. Intravitreal bevacizumab (Avastin) for persistent new vessels in diabetic retinopathy (IBEPE study). Retina (Philadelphia, Pa). 2006;26(9):1006-13. doi: 10.1097/01.iae.0000246884.76018.63 PMID: 17151487
13. Li WW, Hutnik M, Gehr G. Antiangiogenesis in haematological malignancies. British journal of haematology. 2008;143(5):622-. doi: 10.1111/j.1365-2141.2008.07372.x PMID: 19036013
14. Ozaki H, Seo M-S, Ozaki K, Yamada H, Yamada E, Okamoto N, et al. Blockade of Vascular Endothelial Cell Growth Factor Receptor Signaling Is Sufficient to Completely Prevent Retinal Neovascularization. American Journal of Pathology. 2000;156(2):697-707. doi: 10.1016/S0002-9440 (10) 64773-6 PMID: 10666398
15. Pugh CW, Ratcliffe PJ. Regulation of angiogenesis by hypoxia: role of the HIF system. Nature medicine. 2003;9(6):677-84. doi: 10.1038/nm0603-677 PMID: 12778166
16. Goldberg MA, Dunning SP, Bunn HF. Regulation of the erythropoietin gene: evidence that the oxygen sensor is a heme protein. Science. 1988;242(4884):1412-5. PMID: 2849206
17. Epstein AC, Gleadle JM, McNeill LA, Hewitson KS, O'Rourke J, Mole DR, et al. Celegans EGL-9 and Mammalian Homologs Define a Family of Dioxygenases that Regulate HIF by Prolyl Hydroxylation. Cell. 2001;107(1):43-54. PMID: 11595184
18. Yuan Y, Hilliard G, Ferguson T, Millhorn DE. Cobalt inhibits the interaction between hypoxia-inducible factor-alpha and von Hippel-Lindau protein by direct binding to hypoxia-inducible factor-alpha. The Journal of biological chemistry. 2003;278(18):15911-6. doi: 10.1074/jbc. M300463200 PMID: 12606543
19. Liu X-H, Kirschenbaum A, Yao S, Stearns ME, Holland JF, Claffey K, et al. Upregulation of vascular endothelial growth factor by cobalt chloride-simulated hypoxia is mediated by persistent induction of cyclooxygenase-2 in a metastatic human prostate cancer cell line. Clinical & experimental metastasis. 1999;17(8):687-94.
20. Minchenko A, Bauer T, Salceda S, Caro J. Hypoxic stimulation of vascular endothelial growth factor expression in vitro and in vivo. Laboratory investigation; a journal of technical methods and pathology. 1994;71(3):374. PMID: 7933988
21. Hara A, Niwa M, Aoki H, Kumada M, Kunisada T, Oyama T, et al. A new model of retinal photoreceptor cell degeneration induced by a chemical hypoxia-mimicking agent, cobalt chloride. Brain research. 2006;1109(1):192-200. PMID: 16863645
22. Matsumoto M, Makino Y, Tanaka T, Tanaka H, Ishizaka N, Noiri E, et al. Induction of renoprotective gene expression by cobalt ameliorates ischemic injury of the kidney in rats. Journal of the American Society of Nephrology. 2003;14(7):1825-32. PMID: 12819242
23. Shah PK, Narendran V, Tawansy KA, Raghuram A, Narendran K. Intravitreal bevacizumab (Avastin) for post laser anterior segment ischemia in aggressive posterior retinopathy of prematurity. Indian journal of ophthalmology. 2007;55(1):75-6. PMID: 17189897.
24. Barnett JM, Yanni SE, Penn JS. The development of the rat model of retinopathy of prematurity. Documenta ophthalmologica. 2010;120(1):3-12. doi: 10.1007/s10633-009-9180-y PMID: 19639356
25. Rabinowitz R, Priel A, Rosner M, Pri-Chen S, Spierer A. Avastin treatment reduces retinal neovascularization in a mouse model of retinopathy of prematurity. Current eye research. 2012;37(7):624-9. doi: 10.3109/02713683.2012.669003 PMID: 22578253.
26. Yanni SE, McCollum GW. Rodent Models of Oxygen-Induced Retinopathy. Dordrecht: Springer Netherlands; 2008. p. 57-80.
27. Alvarez Y, Kennedy BN, Cederlund ML, Cottell DC, Bill BR, Ekker SC, et al. Genetic determinants of hyaloid and retinal vasculature in zebrafish. BMC developmental biology. 2007;7(1):114-. doi: 10. 1186/1471-213X-7-114
28. Cao R, Jensen LDE, Söll I, Hauptmann G, Cao Y, Södertörns H, et al. Hypoxia-induced retinal angiogenesis in zebrafish as a model to study retinopathy. PloS one. 2008;3(7):e2748. doi: 10.1371/journal. pone.0002748 PMID: 18648503
29. Hartsock A, Lee C, Arnold V, Gross JM. In vivo analysis of hyaloid vasculature morphogenesis in zebrafish: A role for the lens in maturation and maintenance of the hyaloid. Developmental biology. 2014;394(2):327-39. doi: 10.1016/j.ydbio.2014.07.024 PMID: 25127995; PubMed Central PMCID: PMC4172555.
30. Lieschke GJ, Currie PD. Animal models of human disease: zebrafish swim into view. Nature reviews Genetics. 2007;8(5):353-67. doi: 10.1038/nrg2091 PMID: 17440532
31. Peterson RT, Shaw SY, Peterson TA, Milan DJ, Zhong TP, Schreiber SL, et al. Chemical suppression of a genetic mutation in a zebrafish model of aortic coarctation. Nat Biotechnol. 2004;22(5):595-9. Epub 2004/04/21. doi: 10.1038/nbt963 PMID: 15097998.
32. EyeStudy Group. Preclinical and phase 1A clinical evaluation of an anti-VEGF pegylated aptamer (EYE001) for the treatment of exudative age-related macular degeneration. Retina. 2002;22(2):143-52. Epub 2002/04/03. PMID: 11927845.
33. Ferrara N, Gerber HP, Le Couter J. The biology of VEGF and its receptors. Nat Med. 2003;9(6):669-76. Epub 2003/06/05. doi: 10.1038/nm0603-669 PMID: 12778165.
34. Los M, Roodhart JM, Voest EE. Target practice: lessons from phase III trials with bevacizumab and vatalanib in the treatment of advanced colorectal cancer. The Oncologist. 2007;12(4):443-50. PMID: 17470687
35. Schmucker C, Loke YK, Ehlken C, Agostini HT, Hansen LL, Antes G, et al. Intravitreal bevacizumab (Avastin) versus ranibizumab (Lucentis) for the treatment of age-related macular degeneration: a safety review. The British journal of ophthalmology. 2011;95(3):308-17. Epub 2010/10/26. doi: 10.1136/bjo. 2009.178574 PMID: 20971791.
36. Ellis LM, Takahashi Y, Liu W, Shaheen RM. Vascular endothelial growth factor in human colon cancer: biology and therapeutic implications. The oncologist. 2000;5 Suppl 1(90001):11-5. doi: 10.1634/theoncologist.5-suppl-1-11 PMID: 10804085
37. Martin D, Maguire M, Ying G, Grunwald J, Fine S, Jaffe G. Ranibizumab and bevacizumab for neovascular age-related macular degeneration. The New England journal of medicine. 2011;364(20):1897. doi: 10.1056/NEJMoa1102673 PMID: 21526923
38. Cannon JE, Upton PD, Smith JC, Morrell NW. Intersegmental vessel formation in zebrafish: requirement for VEGF but not BMP signalling revealed by selective and non-selective BMP antagonists. Br J Pharmacol. 2010;161(1):140-9. Epub 2010/08/20. doi: 10.1111/j.1476-5381.2010.00871.x PMID: 20718746; PubMed Central PMCID: PMC2962823.
39. Alvarez Y, Astudillo O, Jensen L, Reynolds AL, Waghorne N, Brazil DP, et al. Selective inhibition of retinal angiogenesis by targeting PI3 kinase. PloS one. 2009;4(11):e7867. Epub 2009/11/20. doi: 10. 1371/journal.pone.0007867 PMID: 19924235; PubMed Central PMCID: PMC2773410.
40. Kim J, Oh WJ, Gaiano N, Yoshida Y, Gu C. Semaphorin 3E-Plexin-D1 signaling regulates VEGF function in developmental angiogenesis via a feedback mechanism. Genes Dev. 2011;25(13):1399-411. Epub 2011/07/05. doi: 10.1101/gad.2042011 PMID: 21724832; PubMed Central PMCID: PMC3134083.
41. Chan-Ling T, Tout S, Holländer H, Stone J. Vascular changes and their mechanisms in the feline model of retinopathy of prematurity. Investigative ophthalmology & visual science. 1992;33(7):2128-47.
42. Smith LE, Wesolowski E, McLellan A, Kostyk SK, D'Amato R, Sullivan R, et al. Oxygen-induced retinopathy in the mouse. Investigative ophthalmology & visual science. 1994;35(1):101.
43. Haase VH. The sweet side of HIF. Kidney Int. 2010;78(1):10-3. Epub 2010/06/17. doi: 10.1038/ki. 2010.112 PMID: 20551925; PubMed Central PMCID: PMC3789845.
44. Lobov IB, Renard RA, Papadopoulos N, Gale NW, Thurston G, Yancopoulos GD, et al. Delta-like ligand 4 (Dll4) is induced by VEGF as a negative regulator of angiogenic sprouting. Proc Natl Acad Sci U S A. 2007;104(9):3219-24. Epub 2007/02/14. doi: 10.1073/pnas.0611206104 PMID: 17296940; PubMed Central PMCID: PMC1805530.
45. Lepore D, Quinn GE, Molle F, Baldascino A, Orazi L, Sammartino M, et al. Intravitreal Bevacizumab versus Laser Treatment in Type 1 Retinopathy of Prematurity: Report on Fluorescein Angiographic Findings. Ophthalmology. 2014. doi: 10.1016/j.ophtha.2014.05.015 PMID: 25001158.
46. Castellanos MA, Schwartz S, Garcia-Aguirre G, Quiroz-Mercado H. Short-term outcome after intravitreal ranibizumab injections for the treatment of retinopathy of prematurity. The British journal of ophthalmology. 2013;97(7):816-9. doi: 10.1136/bjophthalmol-2012-302276 PMID: 23221964.
47. Bakri SJ, Snyder MR, Reid JM, Pulido JS, Singh RJ. Pharmacokinetics of intravitreal bevacizumab (Avastin). Ophthalmology. 2007;114(5):855-9. Epub 2007/05/01. doi: 10.1016/j.ophtha.2007.01.017 PMID: 17467524.
48. Travassos A, Teixeira S, Ferreira P, Regadas I, Travassos AS, Esperancinha FE, et al. Intravitreal bevacizumab in aggressive posterior retinopathy of prematurity. Ophthalmic surgery, lasers & imaging: the official journal of the International Society for Imaging in the Eye.. 2007;38(3):233-7. PMID: 17552391.
49. Mintz-Hittner HA, Kuffel RR Jr. Intravitreal injection of bevacizumab (avastin) for treatment of stage 3 retinopathy of prematurity in zone I or posterior zone II. Retina. 2008;28(6):831-8. doi: 10.1097/IAE. 0b013e318177f934 PMID: 18536599.
50. Chung EJ, Kim JH, Ahn HS, Koh HJ. Combination of laser photocoagulation and intravitreal bevacizumab (Avastin) for aggressive zone I retinopathy of prematurity. Graefe's archive for clinical and experimental ophthalmology = Albrecht von Graefes Archiv fur klinische und experimentelle Ophthalmologie.. 2007;245(11):1727-30. doi: 10.1007/s00417-007-0661-y PMID: 17690897.
51. Law JC, Recchia FM, Morrison DG, Donahue SP, Estes RL. Intravitreal bevacizumab as adjunctive treatment for retinopathy of prematurity. Journal of AAPOS: the official publication of the American Association for Pediatric Ophthalmology and Strabismus/American Association for Pediatric Ophthalmology and Strabismus.. 2010;14(1):6-10. doi: 10.1016/j.jaapos.2009.10.011 PMID: 20227614.
52. Lalwani GA, Berrocal AM, Murray TG, Buch M, Cardone S, Hess D, et al. Off-label use of intravitreal bevacizumab (Avastin) for salvage treatment in progressive threshold retinopathy of prematurity. Retina. 2008;28(3 Suppl):S13-8. doi: 10.1097/IAE.0b013e3181644ad2 PMID: 18317338.
53. Chimote G, Sreenivasan J, Pawar N, Subramanian J, Sivaramakrishnan H, Sharma S. Comparison of effects of anti-angiogenic agents in the zebrafish efficacy-toxicity model for translational anti-angiogenic drug discovery. Drug design, development and therapy. 2014;8:1107-23. Epub 2014/08/30. doi: 10. 2147/dddt.s55621 PMID: 25170251; PubMed Central PMCID: PMCPmc4145829.
54. Kimmel CB, Ballard WW, Kimmel SR, Ullmann B, Schilling TF. Stages of embryonic development of the zebrafish. Dev Dyn. 1995;203(3):253-310. Epub 1995/07/01. doi: 10.1002/aja.1002030302 PMID: 8589427.
55. Ballard KW, Fielding PA, Hyman C. Evidence for the Shift of Blood to the Nutritive Circulation during Reactive Hyperaemia. The Journal of physiology. 1964;173:178-89. PMID: 14212238; PubMed Central PMCID: PMC1368864.
56. Nicoli S, Presta M. The zebrafish/tumor xenograft angiogenesis assay. Nat Protoc. 2007;2(11):2918-23. Epub 2007/11/17. doi: 10.1038/nprot.2007.412 PMID: 18007628.
57. Reinardy HC, Syrett JR, Jeffree RA, Henry TB, Jha AN. Cobalt-induced genotoxicity in male zebrafish (Danio rerio), with implications for reproduction and expression of DNA repair genes. Aquatic toxicology. 2013;126:224-30. doi: 10.1016/j.aquatox.2012.11.007 PMID: 23246864.
58. Kajimura S, Aida K, Duan C. Understanding hypoxia-induced gene expression in early development: in vitro and in vivo analysis of hypoxia-inducible factor 1-regulated zebra fish insulin-like growth factor binding protein 1 gene expression. Molecular and cellular biology. 2006;26(3):1142-55. doi: 10.1128/MCB.26.3.1142-1155.2006 PMID: 16428465; PubMed Central PMCID: PMC1347021.
59. Yu RM, Chu DL, Tan TF, Li VW, Chan AK, Giesy JP, et al. Leptin-mediated modulation of steroidogenic gene expression in hypoxic zebrafish embryos: implications for the disruption of sex steroids. Environmental science & technology. 2012;46(16):9112-9. doi: 10.1021/es301758c PMID: 22816610.